KPV is about as small as a bioactive peptide gets: a tripeptide, just three amino acids — lysine (K), proline (P), and valine (V) — corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), specifically the α-MSH(11–13) sequence. Despite its size, KPV is one of the more mechanistically well-characterized anti-inflammatory research peptides, and it was one of the seven compounds the FDA reviewed at its July 2026 compounding advisory meeting. Here's what the preclinical literature reports.
Most of α-MSH's biological activity works through melanocortin receptors (MCRs), a G-protein-coupled receptor family. KPV is notable in the literature precisely because its anti-inflammatory activity in intestinal models does not appear to depend on that classical receptor pathway. Instead, published research (including a study in Gastroenterology) describes KPV as being taken up directly into intestinal epithelial cells by the PepT1 peptide transporter — a transporter that is itself upregulated during intestinal inflammation. Once inside the cell, KPV is reported to inhibit IκB kinase, which suppresses NF-κB nuclear translocation, a central signaling step in triggering inflammatory gene expression. Because this route bypasses cell-surface melanocortin receptors entirely, it's described in the literature as a receptor-independent, transporter-mediated mechanism — mechanistically distinct from most of the rest of the α-MSH signaling literature.
The bulk of the published KPV literature comes from rodent colitis models. Research covered in the peer-reviewed literature reports that orally delivered KPV reduced the severity of both DSS-induced and TNBS-induced colitis in mice — two of the standard chemically induced colitis models used in inflammatory bowel disease research — with reported reductions in pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. An earlier mechanistic study specifically dissecting the anti-inflammatory activity of the α-MSH core sequence versus its C-terminal KPV fragment found that KPV retained meaningful anti-inflammatory effect despite being a much simpler, smaller molecule than the parent hormone.
KPV was one of seven peptides — alongside BPC-157, TB-500, MOTS-c, Semax and Epitalon — reviewed by the FDA's Pharmacy Compounding Advisory Committee (PCAC) at its July 23–24, 2026 meeting for potential inclusion on the 503A Bulks List. As with the other peptides in that group, the FDA's own briefing materials cited a near-total absence of controlled human clinical data as a central concern. Committee recommendations from that meeting are advisory; the FDA retains final decision authority. See our full July 2026 FDA compounding review coverage for the broader context, and how the 503A Bulks List process works generally.
Universe Peptide supplies KPV for in-vitro laboratory research, with a third-party Certificate of Analysis (COA) available for each lot. Confirm the current product listing on our shop before ordering: